ClinicalTrials.gg
CompletedNCT06454630ROXI-VTE IIUpdated May 27, 2026Results posted

A Trial to Learn How Well REGN7508 Works for Preventing Blood Clots After a Knee Replacement in Adult Participants

A Phase 2 interventional study of REGN7508 and Enoxaparin in Venous Thromboembolism, sponsored by Regeneron Pharmaceuticals. Completed at 14 sites in 5 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-05-27.

Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
179
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies in Venous Thromboembolism with a site in Latvia — 2 open to participants now, 2 under way, 1 of them phase 3. Venous Thromboembolism · Latvia.

Enrollment
19th of 19
179 · median 1,146
Started
2024
the only one that year
Phase 2
8 of 22
none open now
Registered
21st of 22
by date
Lead sponsor
3 of 22
Regeneron Pharmaceuticals

Among the 22 studies in Venous Thromboembolism with a site in Latvia, this one is the 19th largest by enrollment of the 19 interventional ones that give a count, is the only one that started in 2024, is one of 8 in phase 2, and was the 21st registered.

Venous Thromboembolism

713 studies on the registry are indexed under Venous Thromboembolism; 147 are open to participants now.

Browse Venous Thromboembolism studies →

Open to participants now

2 of the 22 studies in Venous Thromboembolism with a site in Latvia are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Latvia have not opened yet or have stopped. Only those recruiting at a site in Latvia →

Who these studies take

Of the 113 Venous Thromboembolism studies recruiting now, 90 (80%) set no upper age limit and 13 (12%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Venous Thromboembolism with a site in Latvia, or all of them as a file.
02

Study summary

This study is researching an experimental drug called REGN7508 (called "study drug"). The study is focused on adults undergoing elective, unilateral (one side) total knee replacement (TKR) surgery.

The aim of the study is to see how effective the study drug is at preventing venous thromboembolism (VTE) and other related diseases after unilateral total knee replacement surgery.

The study is looking at several other research questions, including:

  • What side effects may happen from taking the study drug
  • How much study drug is in the blood at different times
  • Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)
03

Conditions studied

  • Venous Thromboembolism

Keywords

  • Anti-factor XI (FXI) monoclonal antibody
  • Venous thromboembolism (VTE)
  • Unilateral total knee arthroplasty (TKA)
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Undergoing a primary elective unilateral TKA
  2. Has a body weight ≤130 kg at screening visit
  3. Is judged by the investigator to be in good health based on medical history, physical examination, vital sign measurements, and (ECG's) performed at screening and/or prior to administration of initial dose of study drug as described in the protocol
  4. Is in good health based on laboratory safety testing obtained during the screening period as described in the protocol

Key Exclusion Criteria:

  1. History of bleeding in the past 6 months prior to dosing requiring hospitalization or transfusion; history of intracranial or intraocular bleeding, excessive operative or post-operative bleeding, and traumatic spinal or epidural anesthesia; history of bleeding diathesis
  2. History of thromboembolic disease or thrombophilia
  3. History of major surgery, including brain, spinal, or ocular, within approximately the past 6 months
  4. History of major trauma within approximately the past 6 months prior to dosing
  5. Hospitalized (>24 hours) for any reason within 30 days of the screening visit
  6. Has an estimated (GFR) of \<45 mL/min/1.73m\^2 at the screening visit using one of the following formulas: the Modification of Diet in Renal Disease (MDRD) equation, the Chronic Kidney Disease Epidemiology Collaboration equation, or equivalent equation

Note: Other protocol-defined Inclusion/ Exclusion Criteria apply

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
179 participants (actual)

Study arms

  • Experimental
    REGN7508

    Drug: REGN7508

  • Active comparator
    Enoxaparin

    Drug: Enoxaparin

Interventions

  • Administered by single intravenous (IV) dose

  • Administered by subcutaneous (SC) dose daily through the time of venography (or day 12, whichever is earlier)

    Also known as: Inhixa

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Confirmed, Adjudicated Venous Thromboembolism (VTE)

    Composite endpoint that includes asymptomatic deep DVT (deep venous thrombosis) detected by unilateral venography of the operated leg; confirmed symptomatic DVT of either leg; confirmed fatal or nonfatal pulmonary embolism (PE) including unexplained death for which PE cannot be ruled out.

    Time frame: Through day 12

Secondary outcomes

  1. Number of Participants With Major Bleeding and Clinically Relevant Non-major (CRNM) Bleeding

    International Society on Thrombosis and Hemostasis (ISTH) criteria for Major Bleeding and CRNM Bleeding as described in the protocol

    Time frame: Through day 12

  2. Percentage of Participants With at Least One Treatment Emergent Adverse Event (TEAE)

    A TEAE is any untoward medical occurrence in a participant administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment.

    Time frame: Through day 75

  3. Percentage of Participants With Major VTE

    Major VTE is a composite endpoint that includes: proximal DVT; confirmed symptomatic DVT of either leg; confirmed fatal or nonfatal PE including unexplained death for which PE cannot be ruled out.

    Time frame: Through day 12

  4. Percentage of Participants With Deep Venous Thrombosis (DVT)

    DVT measured by venography of the operated leg

    Time frame: Through day 12

  5. Concentrations of Total REGN7508 in Serum

    Time frame: Days 1, 5, 10, 30 and 75

  6. Fold Change From Baseline in Activated Partial Thromboplastin Time (aPTT)

    aPTT was used to measure the anticipated anticoagulant effect of REGN7508. Fold change is based on the follow-up value/baseline value within an arm.

    Time frame: Days 1, 5, 10, 30, 75

  7. Fold Change From Baseline in Prothrombin Time (PT)

    PT is a measure of extrinsic and/or common pathway function. Fold change is based on the follow-up value/baseline value within an arm.

    Time frame: Days 1, 5, 10, 30, 75

  8. Number of Participants With Anti-REGN7508 Antibodies by Status

    Immunogenicity characterized by anti-drug antibody (ADA) status

    Time frame: Through end of study; approximately Day 75

  9. Number of Participants With Treatment-Emergent or Treatment-Boosted Anti-REGN7508 Antibodies by Maximum Titer

    Immunogenicity characterized per by ADA status

    Time frame: Through end of study; approximately Day 75

07

Results

Posted Mar 2, 2026

Participant flow

Participant flow — Overall Study
MilestoneREGN7508Enoxaparin
Started12059
Completed11658
Not completed41
Withdrew: Lost to follow-up10
Withdrew: Withdrawal by subject31

Outcome measures

PrimaryPercentage of Participants With Confirmed, Adjudicated Venous Thromboembolism (VTE)

Composite endpoint that includes asymptomatic deep DVT (deep venous thrombosis) detected by unilateral venography of the operated leg; confirmed symptomatic DVT of either leg; confirmed fatal or nonfatal pulmonary embolism (PE) including unexplained death for which PE cannot be ruled out.

Time frame:
Through day 12
Reported as:
Number · percentage of participants
Percentage of Participants With Confirmed, Adjudicated Venous Thromboembolism (VTE)
percentage of participantsREGN7508Enoxaparin
Percentage of Participants With Confirmed, Adjudicated Venous Thromboembolism (VTE)7.117.2
Statistical analysis
  • REGN7508 vs Enoxaparin · Posterior odds ratio: 0.37REGN7508 vs. enoxaparin
SecondaryNumber of Participants With Major Bleeding and Clinically Relevant Non-major (CRNM) Bleeding

International Society on Thrombosis and Hemostasis (ISTH) criteria for Major Bleeding and CRNM Bleeding as described in the protocol

Time frame:
Through day 12
Reported as:
Count of participants · Participants
Number of Participants With Major Bleeding and Clinically Relevant Non-major (CRNM) Bleeding
ParticipantsREGN7508Enoxaparin
Major bleeding00
CRNM bleeding00
SecondaryPercentage of Participants With at Least One Treatment Emergent Adverse Event (TEAE)

A TEAE is any untoward medical occurrence in a participant administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment.

Time frame:
Through day 75
Reported as:
Number · percentage of participants
Percentage of Participants With at Least One Treatment Emergent Adverse Event (TEAE)
percentage of participantsREGN7508Enoxaparin
Percentage of Participants With at Least One Treatment Emergent Adverse Event (TEAE)21.728.8
SecondaryPercentage of Participants With Major VTE

Major VTE is a composite endpoint that includes: proximal DVT; confirmed symptomatic DVT of either leg; confirmed fatal or nonfatal PE including unexplained death for which PE cannot be ruled out.

Time frame:
Through day 12
Reported as:
Number · percentage of participants
Percentage of Participants With Major VTE
percentage of participantsREGN7508Enoxaparin
Percentage of Participants With Major VTE01.7
SecondaryPercentage of Participants With Deep Venous Thrombosis (DVT)

DVT measured by venography of the operated leg

Time frame:
Through day 12
Reported as:
Number · percentage of participants
Percentage of Participants With Deep Venous Thrombosis (DVT)
percentage of participantsREGN7508Enoxaparin
Percentage of Participants With Deep Venous Thrombosis (DVT)7.117.2
SecondaryConcentrations of Total REGN7508 in Serum
Time frame:
Days 1, 5, 10, 30 and 75
Reported as:
Mean · milligrams per liter (mg/L)
Concentrations of Total REGN7508 in Serum
milligrams per liter (mg/L)REGN7508
Day 1 (1 hour post REGN7508 dose)54.3 ± 15.1
Day 529.2 ± 9.94
Day 1020.9 ± 6.46
Day 306.82 ± 3.28
Day 750.696 ± 0.556
SecondaryFold Change From Baseline in Activated Partial Thromboplastin Time (aPTT)

aPTT was used to measure the anticipated anticoagulant effect of REGN7508. Fold change is based on the follow-up value/baseline value within an arm.

Time frame:
Days 1, 5, 10, 30, 75
Reported as:
Mean · Fold Change
Fold Change From Baseline in Activated Partial Thromboplastin Time (aPTT)
Fold ChangeREGN7508Enoxaparin
Day 12.80 ± 0.620—
Day 53.24 ± 0.7531.15 ± 0.265
Day 103.10 ± 0.8561.06 ± 0.123
Day 301.39 ± 0.6121.07 ± 0.227
Day 751.01 ± 0.1901.04 ± 0.214
SecondaryFold Change From Baseline in Prothrombin Time (PT)

PT is a measure of extrinsic and/or common pathway function. Fold change is based on the follow-up value/baseline value within an arm.

Time frame:
Days 1, 5, 10, 30, 75
Reported as:
Mean · Fold Change
Fold Change From Baseline in Prothrombin Time (PT)
Fold ChangeREGN7508Enoxaparin
Day 11.11 ± 0.707—
Day 50.97 ± 0.0920.95 ± 0.077
Day 100.96 ± 0.0860.94 ± 0.066
Day 300.96 ± 0.1251.02 ± 0.265
Day 750.94 ± 0.0840.97 ± 0.198
SecondaryNumber of Participants With Anti-REGN7508 Antibodies by Status

Immunogenicity characterized by anti-drug antibody (ADA) status

Time frame:
Through end of study; approximately Day 75
Reported as:
Count of participants · Participants
Number of Participants With Anti-REGN7508 Antibodies by Status
ParticipantsREGN7508
Negative112
Pre-existing Immunoreactivity2
Treatment-Boosted Response0
Treatment-Emergent Response2
SecondaryNumber of Participants With Treatment-Emergent or Treatment-Boosted Anti-REGN7508 Antibodies by Maximum Titer

Immunogenicity characterized per by ADA status

Time frame:
Through end of study; approximately Day 75
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent or Treatment-Boosted Anti-REGN7508 Antibodies by Maximum Titer
ParticipantsREGN7508
Low (<1,000)1
Moderate (1,000 to 10,000)1
High (>10,000)0

Adverse events

Collected over From signing of informed consent to end of study (up to Day 75). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
REGN75080/120 (0%)2/120 (1.7%)8/120 (6.7%)
Enoxaparin0/59 (0%)0/59 (0%)6/59 (10.2%)
Most frequent serious events
Most frequent serious events
EventREGN7508Enoxaparin
DiverticulitisInfections and infestations1/1200/59
Joint dislocationInjury, poisoning and procedural complications1/1200/59
Most frequent other events
Most frequent other events
EventREGN7508Enoxaparin
NauseaGastrointestinal disorders2/1203/59
Respiratory tract infection viralInfections and infestations0/1203/59
Anaemia postoperativeInjury, poisoning and procedural complications6/1200/59

Baseline characteristics

Safety Analysis Set (SAF): All randomized participants who received any study drug; it is based on the treatment received (as treated).

Age, Continuous
Age, Continuous(years)REGN7508EnoxaparinTotal
Mean66.3 ± 7.5066.6 ± 7.5366.4 ± 7.49
Sex: Female, Male
Sex: Female, Male(Participants)REGN7508EnoxaparinTotal
Female9244136
Male281543
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)REGN7508EnoxaparinTotal
Hispanic or Latino415
Not Hispanic or Latino11558173
Unknown or Not Reported101
Race (NIH/OMB)
Race (NIH/OMB)(Participants)REGN7508EnoxaparinTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White12059179
More than one race000
Unknown or Not Reported000
08

Study locations

14 sites
  • Multi-profile Hospital for Active Treatment Hearth and Brain EAD
    Pleven, 5800, Bulgaria
  • Multiprofile Hospital For Active Treatment Park Hospital Ltd.
    Plovdiv, 4002, Bulgaria
  • Budai Irgalmasrendi Korhaz
    Budapest, 1027, Hungary
  • Szolnoki MAV Hospital
    Szolnok, 5000, Hungary
  • Vidzemes Hospital
    Valmiera, Valmieras Aprinkis LV-4201, Latvia
  • Liepaja Regional Hospital
    Liepāja, LV-3414, Latvia
  • Riga's 2nd Hospital
    Riga, LV-1004, Latvia
  • Hospital of Traumatology and Orthopaedics
    Riga, LV-1005, Latvia
  • Orto Klinika
    Riga, LV-1005, Latvia
  • Lietuvos sveikatos mokslu universiteto ligonine Kauno klinik
    Kaunas, Kaunas County LT-50161, Lithuania
  • Lithuanian University of Health Sciences Kaunas Hospital
    Kaunas, LT-48142, Lithuania
  • Klaipeda University Hospital
    Klaipėda, LT-92288, Lithuania
  • Specjalistyczny Szpital im. E. Szczeklika w Tarnowie
    Tarnów, Lesser Poland Voivodeship 33-100, Poland
  • Clinic of Orthopaedics and Paediatric Orthopaedics
    Lodz, Łódź Voivodeship 92-213, Poland
09

References and documents

Publications

  • Weitz JI, Kithcart AP, O'Brien MP, Levy O, Marin E, Onisko M, Mohammadi KA, Li D, Meagher KA, Chang HH, Olenchock BA, Gutstein DE, Segers A, Roberts RS, Bonaca MP, Raskob GE. Efficacy and safety of REGN9933A2 and REGN7508Cat for preventing postoperative venous thromboembolism (ROXI-VTE-I and ROXI-VTE-II): two randomised, open-label, phase 2 trials. Lancet. 2025 Nov 29;406(10519):2551-2563. doi: 10.1016/S0140-6736(25)02097-5. Epub 2025 Nov 8. PubMed 41218619 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication, or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made results publicly available (e.g., scientific publication, scientific conference, clinical trial registry), the legal authority to share the data, and ensured the ability to protect participant privacy.

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2024 to primary completion in Nov 2024, 4 months.

Results were first posted in Mar 2026, 1 year 3 months after primary completion. A results delay was requested in Nov 2025.

Of 27 phase 2 interventional studies under Venous Thromboembolism, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 50. This study's 4 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2024
First posted
Jun 12, 2024
StartActual
Jun 27, 2024
Primary completionActual
Nov 19, 2024
CompletionActual
Jan 21, 2025
Results delay requested
Nov 3, 2025
Results first posted
Mar 2, 2026
Last update
May 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06454630
Responsible party
Sponsor
First posted
Jun 12, 2024
Start date
Jun 27, 2024
Primary completion
Nov 19, 2024
Completion
Jan 21, 2025
Results posted
Mar 2, 2026
Last update
May 27, 2026

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cenvacibart

Start the discussion